Skip to main content
Heritage Bio Labs · Research use only
Heritage Bio Labs

Triptorelin GnRHCheck methods and identity

How triptorelin was tested for sustained testosterone suppression

2 numbered sourcesSource years 2009, 2026

Peptides are short amino-acid chains joined by peptide bonds. Some trigger hormone release when they first meet a receptor and change that response during continued exposure. Triptorelin is a synthetic ten-amino-acid mimic of gonadotropin-releasing hormone, or GnRH. Sustained exposure reduces pituitary signaling to the testes and lowers testosterone. U.S. prescribing information lists advanced prostate cancer as the approved indication for Trelstar, a triptorelin pamoate product. An older, directly relevant phase III study tested how often a long-acting formulation brought testosterone below a prespecified threshold and kept it there. [1, 2]

The hormone response has two phases. Early stimulation can temporarily increase pituitary hormone output and testosterone. As the pituitary becomes less responsive to sustained stimulation, output falls and the testes receive less signal to make testosterone. The prescribing information describes an initial rise and the possibility that it can temporarily worsen some cancer symptoms. A testosterone value obtained early and one obtained after suppression develops therefore describe different parts of the response. [1]

The 2009 trial enrolled 120 patients with advanced prostate cancer in South Africa. Researchers knew what treatment patients received, and everyone entered the same study group. Approximately 98 percent reached the trial's low-testosterone threshold at the first main assessment, and about 93 percent maintained suppression over the specified follow-up. The trial provides a direct estimate of biochemical suppression in this group over the period the researchers observed. [2]

Testosterone is a meaningful treatment measure because some prostate cancers depend on androgen signaling. Still, a threshold reached in a blood test and a difference in how a patient feels or how long the cancer stays controlled are distinct outcomes. Without a comparison group, the study cannot establish how the formulation performs against another drug on progression, symptoms, or survival. [1, 2]

Sources

Original works cited in this article. Links open the external record in a new tab.

Shop Triptorelin GnRH

Articles from the Heritage Bio Labs research series, with links to the original sources. For research use only; not medical advice. Also available as Markdown or JSON.